Clinical Trial Update: Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating acalabrutinib with rituximab and lenalidomide in relapsed/refractory B-cell non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Non-hodgkin Lymphoma,B Cell | Phase 2 | Status: COMPLETED